


Intas Pharma launches Rituximab biosimilar

02 May 2013 | News | By BioSpectrum Bureau

Intas Pharma launches Rituximab biosimilar



Intas Pharmaceuticals has launched "Mabtas", a biosimilar version of Rituximab, with a view to make Non-Hodgkin's Lymphoma (NHL) treatment cost-effective. Mabtas is competent in treating diseases characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells like Chronic Lymphocytic Leukemia (CLL) and Rheumatoid Arthritis apart from NHL.

Mabtas is Asia's only EU GMP facility of Intas Biopharmaceuticals at Ahmedabad. With the launch of this product, Intas now is the only company to have indigenously developed 6 biosimilars in the domestic market. Intas Biopharmaceuticals is India's first and only biopharmaceutical companies to receive European Union - Good Manufacturing Practice (EU-GMP) certification for its microbial manufacturing facility and only company having product under-registration with EMA.

Intas Biopharmaceuticals is already a leading manufacturer of Erythropoietin, G-CSF and peg G-CSF for India and have introduced world's first biosimilar peg G-CSF. Mabtas marks the first monoclonal antibody (mAb) launch from Intas. With this product Intas joins the ranks of select few Indian companies to launch a mAb product in the domestic market.